Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Procedures for Requests From Tribal Lead Agencies To Use CCDF Funds for Construction or Major Renovation
The Office of Child Care (OCC) under HHS proposes to extend and modify an existing information collection for Tribal Lead Agencies requesting Child Care and Development Fund (CCDF) funds for child care facility construction or renovation. The updated Program Instruction significantly streamlines requirements, reducing burden by 70% from 20 hours to 6 hours per response, cutting 19 pages and eliminating 5 requirements while maintaining statutory compliance under 42 U.S.C. 9858m(c)(6). Comments are due May 11, 2026.
Annual Survey of Refugees Information Collection Extension Request
The Administration for Children and Families (ACF) seeks OMB approval to extend the Annual Survey of Refugees (ASR) through 2027, maintaining the existing survey form for the 2025 and 2026 collection cycles. The ASR collects data from approximately 6,400 refugee households that entered the U.S. within the previous 5 fiscal years, supporting the Office of Refugee Resettlement's congressional reporting requirements under the Refugee Act of 1980.
LIHEAP Household Data Collection Report Reinstatement Request
HHS Administration for Children and Families proposes to reinstate the LIHEAP Household Report (OMB #0970-0060) with proposed changes to reduce reporting burden. States, DC, and Puerto Rico would submit household statistics by assistance type and funding source, while tribal grantees would submit simplified household counts. Comments are due June 8, 2026.
DNV Healthcare Hospital Accreditation Program Continued Approval Application
CMS published notice of DNV Healthcare USA Inc.'s application for continued recognition as a national accrediting organization for its hospital accreditation program under Medicare and Medicaid. The agency seeks public comment on whether DNV meets CMS standards for continued approval. Comments must be submitted by May 11, 2026.
National Eye Institute Board of Scientific Counselors Closed Meeting Notice
The NIH National Eye Institute published a closed meeting notice for the Board of Scientific Counselors on April 27, 2026. The meeting will review and evaluate personnel qualifications and performance, and the competence of individual investigators. The meeting is closed pursuant to FACA exemptions for personal privacy.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review published a notice announcing five closed meetings scheduled for May 5-6, 2026, to review grant applications across topics including aging/neurological/behavioral health, cardiovascular clinical trials, cancer genetics, gene regulation, and pathogenic eukaryotes. All meetings will be held virtually and closed to the public pursuant to the Federal Advisory Committee Act.
HRSA Extends Small Health Care Provider Quality and Delta States Network Programs
HRSA has issued a notice extending two grant programs for rural healthcare providers. The Small Health Care Provider Quality Improvement Program receives a 1-year extension for 21 award recipients (HRSA-22-093 cohort), while the Delta States Network Development Program extends 12 award recipients (HRSA-23-031 cohort). Total funding amounts to $15,928,583 for the period August 1, 2026, through July 31, 2027.
Phosphate-containing copolymers for virulence suppression
The European Patent Office published patent application EP4182377A1 for 3M Innovative Properties Company's phosphate-containing copolymers designed to suppress bacterial virulence. The invention covers copolymer compositions targeting A61P 31/04 (anti-infectives). Designated states cover all EU member states plus additional European countries.
Hydroxyureamethyl Acylfulvene for Treating Brain Cancer or CNS Cancer
The European Patent Office published patent EP4132489A1 on April 1, 2026, granting Lantern Pharma Inc. exclusive rights to hydroxyureamethyl acylfulvene for treating brain cancer or CNS cancer. The patent names inventors Kulkarni and Bhatia and covers the compound, formulations, and methods of treatment using the drug. This provides Lantern Pharma with patent protection in 34 EPC contracting states for 20 years from the filing date.
Treatment for Depression with Positive Allosteric Modulator of AMPA
The European Patent Office published patent application EP4149478A1 for Takeda Pharmaceutical Company Limited, covering a treatment for depression using a positive allosteric modulator of AMPA (AMPA receptor). The patent was published on April 1, 2026, with inventors including Pathi Jagannatham, Naga Venkatesha Murthy, Asgharnejad Mahnaz, and Xu Lin. The designated states include 27 European countries covering major pharmaceutical markets.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
737 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.